Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1957 1
1958 1
1959 1
1960 1
1962 1
1964 2
1965 2
1966 2
1967 3
1968 4
1969 5
1970 4
1971 8
1972 2
1973 6
1974 7
1975 3
1976 2
1977 17
1978 13
1979 20
1980 18
1981 20
1982 21
1983 29
1984 25
1985 45
1986 23
1987 34
1988 15
1989 16
1990 20
1991 19
1992 17
1993 24
1994 14
1995 22
1996 18
1997 20
1998 21
1999 33
2000 32
2001 20
2002 36
2003 28
2004 32
2005 44
2006 49
2007 54
2008 45
2009 49
2010 47
2011 55
2012 49
2013 45
2014 58
2015 59
2016 49
2017 41
2018 51
2019 42
2020 69
2021 93
2022 83
2023 79
2024 63

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,696 results

Results by year

Filters applied: . Clear all
Page 1
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC. Dimopoulos MA, et al. Among authors: iida s. Blood Cancer J. 2020 Feb 13;10(2):17. doi: 10.1038/s41408-020-0273-x. Blood Cancer J. 2020. PMID: 32054831 Free PMC article. Review.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Among authors: iida s. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Usmani SZ, et al. Among authors: iida s. Haematologica. 2022 Oct 1;107(10):2408-2417. doi: 10.3324/haematol.2021.279459. Haematologica. 2022. PMID: 35354247 Free PMC article. Clinical Trial.
Clinical landscape of TP73 structural variants in ATL patients.
Hiramatsu H, Yokomori R, Shengyi L, Tanaka N, Mori S, Kiyotani K, Gotoh O, Kusumoto S, Nakano N, Suehiro Y, Ito A, Choi I, Ohtsuka E, Hidaka M, Nosaka K, Yoshimitsu M, Imaizumi Y, Iida S, Utsunomiya A, Noda T, Nishikawa H, Ueda R, Sanda T, Ishida T. Hiramatsu H, et al. Among authors: iida s. Leukemia. 2023 Dec;37(12):2502-2506. doi: 10.1038/s41375-023-02059-9. Epub 2023 Oct 20. Leukemia. 2023. PMID: 37864123 Free PMC article. No abstract available.
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Suzuki K, Wechalekar AD, Kim K, Shimazaki C, Kim JS, Ikezoe T, Min CK, Zhou F, Cai Z, Chen X, Iida S, Katoh N, Fujisaki T, Shin HJ, Tran N, Qin X, Vasey SY, Tromp B, Weiss BM, Comenzo RL, Kastritis E, Lu J. Suzuki K, et al. Among authors: iida s. Ann Hematol. 2023 Apr;102(4):863-876. doi: 10.1007/s00277-023-05090-z. Epub 2023 Mar 2. Ann Hematol. 2023. PMID: 36862168 Free PMC article. Clinical Trial.
Lineage- and Stage-Specific Oncogenicity of IRF4.
Amanda S, Tan TK, Iida S, Sanda T. Amanda S, et al. Among authors: iida s. Exp Hematol. 2022 Oct;114:9-17. doi: 10.1016/j.exphem.2022.07.300. Epub 2022 Jul 29. Exp Hematol. 2022. PMID: 35908629 Free article. Review.
Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection.
Miyamoto S, Nishiyama T, Ueno A, Park H, Kanno T, Nakamura N, Ozono S, Aihara K, Takahashi K, Tsuchihashi Y, Ishikane M, Arashiro T, Saito S, Ainai A, Hirata Y, Iida S, Katano H, Tobiume M, Tokunaga K, Fujimoto T, Suzuki M, Nagashima M, Nakagawa H, Narita M, Kato Y, Igari H, Fujita K, Kato T, Hiyama K, Shindou K, Adachi T, Fukushima K, Nakamura-Uchiyama F, Hase R, Yoshimura Y, Yamato M, Nozaki Y, Ohmagari N, Suzuki M, Saito T, Iwami S, Suzuki T. Miyamoto S, et al. Among authors: iida s. Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2314808120. doi: 10.1073/pnas.2314808120. Epub 2023 Dec 22. Proc Natl Acad Sci U S A. 2023. PMID: 38134196 Free PMC article.
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.
Kogure Y, Handa H, Ito Y, Ri M, Horigome Y, Iino M, Harazaki Y, Kobayashi T, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Shinozaki T, Yoshida T, Mori I, Iida S, Maeda T, Kataoka K. Kogure Y, et al. Among authors: iida s. Blood. 2024 Jun 6;143(23):2401-2413. doi: 10.1182/blood.2023022540. Blood. 2024. PMID: 38427753 Free article.
1,696 results